Back to News
Feb 25, 2026 12:01 PM

Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy

Arcellx Inc. (NASDAQ:ACLX) shares rose on Wednesday after Gilead Sciences Inc. (NASDAQ:GILD) agreed to acquire the company for $7.8 billion, or $115 per share in cash.

While Gilead's acquisition values Arcellx at an implied $7.8 billion in equity, it includes a $5-per-share contingent value right.

The deal strengthens Gilead's oncology portfolio, centered on anito-cel, a CAR T-cell therapy for multiple myeloma that has delivered promising clinical results. The company said the transaction will accelerate the commercialization of the therapy.

ACLX Bearish Trend Below SMA Indicators

During Wednesday’s pre-market session, the stock was trading ...